Want to see VRPX full AI Analyst Report?
Virpax Pharmaceuticals (VRPX) AI Stock Analysis
Virpax Pharmaceuticals
(Other OTC:VRPX)
The score is primarily constrained by very weak financial performance (no revenue, recurring losses, sharply higher 2024 losses and cash burn, and negative equity), which elevates financing and dilution risk. Technicals are also weak with the price below key moving averages, while valuation metrics provide little support due to non-meaningful P/E and no dividend yield data.
Virpax Pharmaceuticals (VRPX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $994
- Dividend Yield
- ―
- Average Volume (3M)
- 785
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- -18790.74
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Virpax Pharmaceuticals Business Overview & Revenue Model
Company Description
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addict...
How the Company Makes Money
Virpax Pharmaceuticals makes money through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company's revenue model includes licensing agreements with other pharmaceutical companies and p...
Virpax Pharmaceuticals Financial Statement Overview
Summary
Income statement shows no revenue with persistent and worsening losses, including a sharp deterioration in 2024. Cash flow remains deeply negative with a dramatic increase in 2024 cash burn, indicating heavy dependence on external funding. While debt is zero, the shift to negative equity in 2024 materially increases financial fragility and dilution risk.
Income Statement
6Very NegativeBalance Sheet
18Very NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -3.36M | -11.96M | -2.25M | -3.31M | 62.26K | 4,000 |
| Net Income | -12.07M | -12.07M | -15.19M | -21.46M | -12.15M | -4.49M |
Balance Sheet | ||||||
| Total Assets | 1.56M | 1.56M | 9.63M | 19.67M | 39.57M | 465.41K |
| Cash, Cash Equivalents and Short-Term Investments | 1.51M | 1.51M | 9.14M | 19.00M | 36.84M | 54.80K |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 1.57M |
| Total Liabilities | 2.47M | 2.47M | 7.69M | 3.09M | 2.09M | 4.68M |
| Stockholders Equity | -913.76K | -913.76K | 1.93M | 16.58M | 37.48M | -4.22M |
Cash Flow | ||||||
| Free Cash Flow | -16.71M | -16.71B | -9.85M | -17.85M | -14.54M | -1.38M |
| Operating Cash Flow | -16.71M | -16.71B | -9.85M | -17.85M | -14.54M | -1.38M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 9.08M | 9.08B | 0 | 0 | 51.33M | 1.40M |
Virpax Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRPX, the sentiment is Positive. The current price of 0.15 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.03, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 99.86 is Negative, neither overbought nor oversold. The STOCH value of 74.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRPX.
Virpax Pharmaceuticals Risk Analysis
Virpax Pharmaceuticals disclosed 70 risk factors in its most recent earnings report. Virpax Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVirpax Pharmaceuticals Peers Comparison
Overall Rating
- VRPX40Underperform
SCNI37Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VRPX | Virpax Pharmaceuticals, Inc. | 0.15 | 0.14 | 675.00% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.47 | -12.23 | -96.29% | |
| ADTX | Aditxt, Inc. | 0.04 | -1406.12 | -100.00% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.11 | -91.74% | |
| PBM | Psyence Biomedical Ltd. | 3.31 | -15.44 | -82.35% | |
| CDT | Cdt Equity Inc. | 0.07 | -15624.93 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 30, 2025